In last trading session, BioNTech SE ADR (NASDAQ:BNTX) saw 0.51 million shares changing hands with its beta currently measuring 0.23. Company’s recent per share price level of $118.22 trading at $0.58 or 0.49% at ring of the bell on the day assigns it a market valuation of $28.10B. That closing price of BNTX’s stock is at a discount of -11.22% from its 52-week high price of $131.49 and is indicating a premium of 35.26% from its 52-week low price of $76.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.26 million shares which gives us an average trading volume of 955.38K if we extend that period to 3-months.
For BioNTech SE ADR (BNTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.79. Splitting up the data highlights that, out of 13 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.61 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioNTech SE ADR (NASDAQ:BNTX) trade information
Upright in the green during last session for gaining 0.49%, in the last five days BNTX remained trading in the green while hitting it’s week-highest on Wednesday, 09/25/24 when the stock touched $118.22 price level, adding 1.28% to its value on the day. BioNTech SE ADR’s shares saw a change of 12.01% in year-to-date performance and have moved 5.29% in past 5-day. BioNTech SE ADR (NASDAQ:BNTX) showed a performance of 34.04% in past 30-days. Number of shares sold short was 2.68 million shares which calculate 2.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 133.5 to the stock, which implies a rise of 11.45% to its current value. Analysts have been projecting 81 as a low price target for the stock while placing it at a high target of 359. It follows that stock’s current price would jump 31.48% in reaching the projected high whereas dropping to the targeted low would mean a gain of 31.48% for stock’s current value.
BioNTech SE ADR (BNTX) estimates and forecasts
Statistics highlight that BioNTech SE ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company added 28.15% of value to its shares in past 6 months, showing an annual growth rate of -172.77% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -27.50% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 741.62M for the same. And 11 analysts are in estimates of company making revenue of 1.85B in the next quarter.
BioNTech SE ADR (NASDAQ:BNTX)’s Major holders
BAILLIE GIFFORD & CO is the top institutional holder at BNTX for having 8.28 million shares of worth $665.08 million. And as of 2024-06-30, it was holding 3.4408 of the company’s outstanding shares.
The second largest institutional holder is PRIMECAP MANAGEMENT CO/CA/, which was holding about 4.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.9912 of outstanding shares, having a total worth of $384.89 million.
